LIVE Stocks surge after Trump retakes the White House. Follow our live blog. Stockholm - Delayed Quote ? SEK Spago Nanomedical AB (publ) (SPAGO.ST) Follow Compare 0.2000 0.0000 (0.00%) At close: 12:35 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Spago Nanomedical Interim Report January-September 2024 LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad program JULY - SEPTEMBER IN BRIEF Net sales for the quarter amounted to KSEK 485 (KSEK 271) The loss for the quarter amounted to KSEK ... ACCESSWIRE ? 11 hours ago 7UX.F SPAGO.ST 0.00% Nomination Committee Appointed for Spago Nanomedical’s Annual General Meeting 2025 LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM"), a nomination committee for the 2025 AGM has been ... ACCESSWIRE ? 16 days ago SPAGO.ST 0.00% 7UX.F Spago Nanomedical in New Phase with Full Focus on the Tumorad Program LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused on the development of Tumorad with the company's ... ACCESSWIRE ? last month 7UX.F SPAGO.ST 0.00% Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group LUND, SE / ACCESSWIRE / August 27, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the independent Data Monitoring Committee (DMC) recommends to proceed the clinical phase I/IIa study Tumorad-01 ... ACCESSWIRE ? 2 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Interim Report January-June 2024 LUND, SE / ACCESSWIRE / August 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Clinical and non-clinical progress in the Tumorad program APRIL - JUNE IN BRIEF Net sales for the quarter amounted to KSEK 459 (KSEK 114) The loss for the quarter ... ACCESSWIRE ? 2 months ago SPAGO.ST 0.00% 7UX.F Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB LUND, SE / ACCESSWIRE / June 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2024, at which the AGM resolved to approve the income statement and balance ... ACCESSWIRE ? 4 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12 LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has received declarations of intent from, among others, the Company's largest owner, Peter Lindell, ... ACCESSWIRE ? 5 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned LUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad-01 are actively recruiting patients. So far two patients ... ACCESSWIRE ? 5 months ago 7UX.F SPAGO.ST 0.00% The Exercise Period for Spago Nanomedical's Warrants of Series TO12 Commences Today LUND, SE / ACCESSWIRE / May 17, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") issued a total of 127,321,212 warrants of series TO12 ("Warrants") within the framework of a rights ... ACCESSWIRE ? 5 months ago SPAGO.ST 0.00% 7UX.F Notice To Annual General Meeting of Spago Nanomedical AB (Publ) LUND, SWEDEN / ACCESSWIRE / May 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) This English version of the notice to the annual general meeting is for convenience only. The Swedish version prevails in the event of any inconsistency. The shareholders ... ACCESSWIRE ? 5 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Interim Report January-March 2024 LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important year JANUARY - MARCH IN BRIEF Net sales for the quarter amounted to KSEK 350 (KSEK 88) The loss for the quarter amounted to KSEK -7.763 ... ACCESSWIRE ? 6 months ago SPAGO.ST 0.00% 7UX.F Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from a non-clinical study exploring 177Lu-SN201 in a model for triple-negative breast cancer. In the model, 177Lu-SN201 ... ACCESSWIRE ? 6 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Strengthens Management with Head of CMC & Supply LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply. Birgitta, an experienced CMC project manager ... ACCESSWIRE ? 6 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Year-end Report January-December, 2023 LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad?OCTOBER - DECEMBER IN BRIEF Net sales for the quarter amounted to KSEK 731 (KSEK 142) The loss for the quarter amounted ... ACCESSWIRE ? 8 months ago SPAGO.ST 0.00% 7UX.F Spago Nanomedical Presents at Redeye's Fight Cancer Event on January 24 LUND, SWEDEN / ACCESSWIRE / January 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company will participate at Redeye's Fight Cancer event on January 24, 2024. At the event, Spago Nanomedical's ... ACCESSWIRE ? 9 months ago 7UX.F SPAGO.ST 0.00% Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01 LUND, SE / ACCESSWIRE / January 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent data monitoring committee has recommended a dose escalation in the company's clinical phase I/IIa ... ACCESSWIRE ? 9 months ago SPAGO.ST 0.00% 7UX.F Spago Nanomedical Reports Positive Top Line Data from Clinical Phase IIa Study SPAGOPIX-02 In Patients with Endometriosis LUND, SE / ACCESSWIRE / December 15, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announces today that the analysis of data from the phase IIa clinical study SPAGOPIX-02 with the contrast agent pegfosimer manganese ... ACCESSWIRE ? 10 months ago SPAGO.ST 0.00% 7UX.F First Patient Dosed in Spago Nanomedical's Clinical Phase I/IIa Study within the Tumorad(R) Program LUND, SE / ACCESSWIRE / December 07, 2023 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the first cancer patient has successfully been dosed in the clinical phase I/IIa study Tumorad-01 with the candidate ... ACCESSWIRE ? 10 months ago SPAGO.ST 0.00% 7UX.F Last Day of the Subscription Period in Spago Nanomedical’s Rights Issue NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG-KONG, JAPAN, CANADA, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OR PUBLICATION ... ACCESSWIRE ? 11 months ago SPAGO.ST 0.00% 7UX.F Nomination Committee Appointed for Spago Nanomedical’s Annual General Meeting 2024 LUND, SE / ACCESSWIRE / November 14, 2023 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM") 2022, a nomination committee for the 2024 AGM has ... ACCESSWIRE ? 11 months ago SPAGO.ST 0.00% 7UX.F Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return SPAGO.ST OMX Stockholm 30 Index YTD -38.84% +6.46% 1-Year -19.46% +20.05% 3-Year -96.30% +9.82%
